Securian Asset Management Inc. Trims Stock Holdings in Biogen Inc. $BIIB

Securian Asset Management Inc. decreased its holdings in Biogen Inc. (NASDAQ:BIIB) by 43.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,945 shares of the biotechnology company’s stock after selling 3,005 shares during the period. Securian Asset Management Inc.’s holdings in Biogen were worth $694,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BIIB. Pure Financial Advisors LLC bought a new position in shares of Biogen in the fourth quarter valued at approximately $206,000. NewEdge Wealth LLC bought a new position in shares of Biogen in the fourth quarter valued at approximately $435,000. F m Investments LLC bought a new position in shares of Biogen in the fourth quarter valued at approximately $434,000. Chesapeake Capital Corp IL bought a new position in shares of Biogen in the fourth quarter valued at approximately $624,000. Finally, Crossmark Global Holdings Inc. boosted its position in shares of Biogen by 175.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 10,094 shares of the biotechnology company’s stock valued at $1,776,000 after acquiring an additional 6,436 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BIIB shares. Guggenheim raised their price objective on shares of Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Sanford C. Bernstein cut their price objective on shares of Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. TD Cowen raised their price objective on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 9th. BMO Capital Markets raised their price objective on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. Finally, Piper Sandler upgraded shares of Biogen from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $177.00 to $214.00 in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $214.23.

Biogen Trading Down 6.4%

Shares of Biogen stock opened at $191.37 on Friday. Biogen Inc. has a 1 year low of $119.18 and a 1 year high of $205.97. The firm has a market cap of $28.25 billion, a PE ratio of 20.53, a PEG ratio of 1.80 and a beta of 0.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a 50 day simple moving average of $185.15 and a two-hundred day simple moving average of $179.24.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the business posted $3.02 earnings per share. Biogen’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts expect that Biogen Inc. will post 14.21 earnings per share for the current fiscal year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said diranersen produced robust tau reductions and showed cognitive benefit signals in early Alzheimer’s disease, supporting plans to move the program into Phase 3 development. Biogen Shares Jump 10% After Advancing Alzheimer’s Tau Drug
• Positive Sentiment: Several analysts remained upbeat after the CELIA data, with buy ratings and price-target support implying Wall Street sees the tau program as more de-risked than before. Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
• Positive Sentiment: Biogen also completed its acquisition of Apellis Pharmaceuticals, which could strengthen near-term growth by adding commercial products and broadening the company’s revenue base. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Biogen’s Alzheimer’s pipeline remains in focus, with additional coverage noting the company still appears likely to win approval for a subcutaneous Leqembi formulation, though the FDA timeline has been delayed. Biogen’s ‘Leqembi’ Subcutaneous Approval Still Likely Despite FDA Delay, RBC Says
• Negative Sentiment: The stock also faced some skepticism because CELIA missed its primary endpoint, which is tempering enthusiasm even as investors react positively to the biomarker and cognitive signals. Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.